ProQR Therapeutics (PRQR) Projected to Post Quarterly Earnings on Wednesday

ProQR Therapeutics (NASDAQ:PRQR) is anticipated to release its earnings data before the market opens on Wednesday, March 12th. Analysts expect ProQR Therapeutics to post earnings of ($0.10) per share and revenue of $6.22 million for the quarter.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR opened at $1.81 on Tuesday. ProQR Therapeutics has a 52-week low of $1.61 and a 52-week high of $4.62. The company has a market cap of $147.84 million, a P/E ratio of -5.66 and a beta of 0.24. The stock’s 50-day simple moving average is $2.32 and its 200 day simple moving average is $2.63.

Analysts Set New Price Targets

Several research firms have weighed in on PRQR. Oppenheimer initiated coverage on ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 price target on the stock. Chardan Capital reiterated a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Finally, Citigroup upgraded ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a report on Monday. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.17.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).